Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewei She

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
European Journal of Epidemiology|November 16, 2006
Chronic obstructive pulmonary disease severity and cardiovascular outcomesSuellen M Curkendall, Stephan Lanes, Cynthia de Luise, et al.
Annals of Neurology|March 16, 2021
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder BiomarkerOrhan Aktas, Michael A Smith, William A Rees, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum StudyEoin P Flanagan, Michael Levy, Eliezer Katz, et al.
The Lancet. Respiratory Medicine|August 2, 2015
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trialChristopher E Brightling, Pascal Chanez, Richard Leigh, et al.
Annals of Clinical and Translational Neurology|May 12, 2026
Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior ImmunosuppressantsBruce A C Cree, Beatrice Suero, Sarah Walsh, et al.
The Lancet. Respiratory Medicine|September 12, 2014
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyChristopher E Brightling, Eugene R Bleecker, Reynold A Panettieri, et al.
The European Respiratory Journal|June 30, 2012
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEdward Piper, Christopher Brightling, Robert Niven, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2006
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparationsRobert L Atmar, Wendy A Keitel, Shital M Patel, et al.
The Journal of Infectious Diseases|April 6, 2006
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adultsJohn J Treanor, Gilbert M Schiff, Robert B Couch, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
European Journal of Epidemiology|November 16, 2006
Chronic obstructive pulmonary disease severity and cardiovascular outcomesSuellen M Curkendall, Stephan Lanes, Cynthia de Luise, et al.
Annals of Neurology|March 16, 2021
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder BiomarkerOrhan Aktas, Michael A Smith, William A Rees, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum StudyEoin P Flanagan, Michael Levy, Eliezer Katz, et al.
The Lancet. Respiratory Medicine|August 2, 2015
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trialChristopher E Brightling, Pascal Chanez, Richard Leigh, et al.
Annals of Clinical and Translational Neurology|May 12, 2026
Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior ImmunosuppressantsBruce A C Cree, Beatrice Suero, Sarah Walsh, et al.
The Lancet. Respiratory Medicine|September 12, 2014
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyChristopher E Brightling, Eugene R Bleecker, Reynold A Panettieri, et al.
The European Respiratory Journal|June 30, 2012
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEdward Piper, Christopher Brightling, Robert Niven, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2006
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparationsRobert L Atmar, Wendy A Keitel, Shital M Patel, et al.
The Journal of Infectious Diseases|April 6, 2006
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adultsJohn J Treanor, Gilbert M Schiff, Robert B Couch, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Pageof 4